The raised IgA in alcohol-associated liver disease may be doing something

Design

Single-centre cross-sectional human study with liver-biopsy subcohort, plus chronic-plus-binge ethanol mouse model and in vitro monocyte experiments

Population

276 adults with alcohol-associated liver disease, 177 with chronic hepatitis B, 20 healthy controls; 16 mice

Primary outcome

Association of circulating and hepatic IgA and myeloid IgA binding with interleukin-1 beta-linked inflammation and hepatocyte injury

Effect

Serum IgA median 323-412 mg/dL in alcohol-associated disease vs 194/211 mg/dL (p<0.001), correlating with hepatic IgA area (rho 0.680) and IL1B transcripts (rho 0.383, p=0.008). Fingolimod in mice reduced serum IgA, IgA-bound macrophages and Il1b transcripts, and attenuated transaminase rise. Secretory IgA plus lipopolysaccharide raised monocyte TNF-alpha and IL-1beta by 280 and 798 pg/mL over lipopolysaccharide alone

A raised serum IgA in alcohol-associated liver disease is a familiar laboratory observation, generally treated as a marker of chronic mucosal exposure rather than as a participant. This study asks whether it drives inflammation.

In 276 consecutive adults with alcohol-associated liver disease, compared against 177 with chronic hepatitis B and 20 healthy controls, serum IgA was markedly higher (median 323-412 mg/dL against 194 and 211). It correlated strongly with the amount of IgA in the liver on immunohistochemistry, and more modestly with interleukin-1 beta transcripts normalised to macrophage content. Hepatic CD14-positive myeloid cells from alcohol-associated disease bound more IgA than those from hepatitis B — a difference in the cells, not just in the quantity of antibody.

The mechanistic work supports the direction. Monocytes stimulated on plate-bound secretory IgA plus lipopolysaccharide released substantially more tumour necrosis factor alpha and interleukin-1 beta than lipopolysaccharide alone, and their conditioned media killed more hepatocyte-line cells. In ethanol-fed mice, fingolimod reduced serum IgA, IgA-bound macrophages, interleukin-1 beta transcripts and the transaminase rise.

Fingolimod is a multiple sclerosis drug and this is not a treatment result. What changes is how to read the number: a high IgA in this setting may index an inflammatory mechanism rather than merely reflect one.

• Do not use fingolimod for alcohol-associated liver disease; this is a mouse experiment
• The human data are cross-sectional and show association, not causation
• Note the contrast with hepatitis B — the difference lay in myeloid IgA binding, not just IgA level
• Abstinence remains the only intervention with established benefit in this disease
• Watch for interleukin-1 pathway targeting in alcohol-associated hepatitis trials

Why it matters

It offers a mechanism for a laboratory abnormality clinicians have recorded for decades without asking what it does.

Don't overread it

Cross-sectional human data with mouse intervention; fingolimod has not been tested as a treatment in people with this disease.

The statistics, in plain English

The correlation between serum IgA and hepatic IgA area is strong (rho 0.680), but the correlation with the inflammatory transcript is modest (rho 0.383), meaning IgA level explains only about 15% of the variation in that measure. The mouse correlation of 0.844 comes from 16 animals, where correlations are unstable. The human component is cross-sectional, so it cannot establish that IgA precedes inflammation rather than accompanying it.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.